2018
DOI: 10.1093/jjco/hyy053
|View full text |Cite
|
Sign up to set email alerts
|

Drug review: Pazopanib

Abstract: Pazopanib (Votrient®) is an oral small-molecule multi-kinase inhibitor that primarily inhibits vascular endothelial growth factor receptor-1, -2 and -3, platelet endothelial growth factor receptor-α, and -β, and the stem-cell factor receptor c-kit. In preliminary experiments using angiogenesis models with mice and rabbits, pazopanib inhibited angiogenesis caused by combined vascular endothelial growth factor and basic fibroblast growth factor. Although pazopanib was developed as a therapeutic agent against var… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
58
0
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 96 publications
(59 citation statements)
references
References 71 publications
0
58
0
1
Order By: Relevance
“…Although some biomarkers of RCC have been suggested [ 40 ], no RCC-specific therapeutic target has been identified. The most common therapeutics are anti-angiogenic and include pazopanib [ 41 ] and sorafenib (which target vascular endothelial growth factor receptor (VEGFR)) [ 42 ] or anti-anabolic (e.g., rapamycin [ 43 ], which targets mTOR). However, RCC is resistant to radiation, chemotherapy, and targeted therapy, which results in a poor prognosis.…”
Section: Discussionmentioning
confidence: 99%
“…Although some biomarkers of RCC have been suggested [ 40 ], no RCC-specific therapeutic target has been identified. The most common therapeutics are anti-angiogenic and include pazopanib [ 41 ] and sorafenib (which target vascular endothelial growth factor receptor (VEGFR)) [ 42 ] or anti-anabolic (e.g., rapamycin [ 43 ], which targets mTOR). However, RCC is resistant to radiation, chemotherapy, and targeted therapy, which results in a poor prognosis.…”
Section: Discussionmentioning
confidence: 99%
“…Pazopanib is a multitargeted tyrosine kinase inhibitor that principally inhibits VEGFR, producing block of tumor angiogenesis and growth. Pazopanib is currently approved for the treatment of renal cell carcinoma and advanced STS [3].…”
Section: Discussionmentioning
confidence: 99%
“…Nonetheless, the exact reasons for the discrepancy are unknown. Pazopanib is another multitarget TKI that has a high probability of causing pneumothorax in patients with sarcomas [8,17,18]; the targets of pazopanib are also different from those of apatinib (Table 3) [19]. Different targets result in different effectiveness of the two TKIs for osteosarcoma treatment.…”
Section: Discussionmentioning
confidence: 99%